DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer

被引：0
|
作者：
Varun Sasidharan Nair
Salman M. Toor
Rowaida Z. Taha
Hibah Shaath
Eyad Elkord
机构：
[1] Qatar Foundation,Cancer Research Center, Qatar Biomedical Research Institute, College of Science and Engineering, Hamad Bin Khalifa University
[2] Institute of Cancer Sciences,undefined
[3] University of Manchester,undefined
来源：
Clinical Epigenetics | 2018年 / 10卷
关键词：
Colorectal cancer; Immune checkpoints; PD-L1; Galectin-9; DNA methylation; Histone trimethylation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
    Pandey, Pratibha
    Khan, Fahad
    Qari, Huda A.
    Upadhyay, Tarun Kumar
    Alkhateeb, Abdulhameed F.
    Oves, Mohammad
    PHARMACEUTICALS, 2022, 15 (03)
  • [22] MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
    Arefeh Zabeti Touchaei
    Sogand Vahidi
    Cancer Cell International, 24
  • [23] Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
    Tunger, Antje
    Kiessler, Maximilian
    Wehner, Rebekka
    Temme, Achim
    Meier, Friedegund
    Bachmann, Michael
    Schmitz, Marc
    BIOMEDICINES, 2018, 6 (01)
  • [24] DNA methylation in the promoters of PD-L1, MMP9, ARG1, galectin-9, TIM-3, VISTA and TGF-β genes in HLA-DR- myeloid cells, compared with HLA-DR+ antigen-presenting cells
    Saleh, Reem
    Toor, Salman M.
    Taha, Rowaida Z.
    Al-Ali, Dana
    Sasidharan Nair, Varun
    Elkord, Eyad
    EPIGENETICS, 2020, 15 (12) : 1275 - 1288
  • [25] Retrospective Analyses of PD-L1, LAG-3, TIM-3, OX40L Expressions and MSI Status in Gastroenteropancreatic Neuroendocrine Neoplasms
    Gurler, Fatih
    Esen, Selin Akturk
    Inci, Bediz Kurt
    Sutcuoglu, Osman
    Ucar, Gokhan
    Akdogan, Orhun
    Uncu, Dogan
    Turhan, Nesrin
    Akyurek, Nalan
    Ozdemir, Nuriye
    Ozet, Ahmet
    Yazici, Ozan
    CANCER INVESTIGATION, 2024, 42 (02) : 141 - 154
  • [26] Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a systematic review and meta-analysis
    Song, Dandan
    Hou, Shufu
    Ma, Ning
    Yan, Bing
    Gao, Jing
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [27] Feto-maternal immune regulation by TIM-3/galectin-9 pathway and PD-1 molecule in mice at day 14.5 of pregnancy
    Meggyes, Matyas
    Lajko, Adrienn
    Palkovics, Tamas
    Totsimon, Anett
    Illes, Zsolt
    Szereday, Laszlo
    Miko, Eva
    PLACENTA, 2015, 36 (10) : 1153 - 1160
  • [28] Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
    Feng, Yuqian
    Jin, Huimin
    Guo, Kaibo
    Xiang, Yuying
    Zhang, Yiting
    Du, Wurong
    Shen, Minhe
    Ruan, Shanming
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [29] The Role of the Immune Checkpoint Molecules PD-1/PD-L1 and TIM-3/Gal-9 in the Pathogenesis of Preeclampsia-A Narrative Review
    Mittelberger, Johanna
    Seefried, Marina
    Franitza, Manuela
    Garrido, Fabian
    Ditsch, Nina
    Jeschke, Udo
    Dannecker, Christian
    MEDICINA-LITHUANIA, 2022, 58 (02):
  • [30] Effects and Mechanisms of Checkpoint Inhibitors (CTLA-4, PD-1 and PD-L1 Inhibitors) as New Immunotherapeutic Agents for Bladder Cancer
    Celik, Serdar
    Altun, Zekiye Sultan
    Aktas, Safiye
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2018, 17 (01): : 18 - 25
12345